Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 10/20 | 0.47 |
| ▸ | CTSK | P43235 | 9/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7337844 | 0.90 | TDP1 (0.45) | TDP1MEN1GAAKMT2ACTSS | |
| SCHEMBL1519817 | 0.89 | MEN1 (0.60) | TDP1MEN1GAAKMT2ACTSS | |
| SCHEMBL7546189 | 0.88 | TDP1 (0.42) | TDP1MEN1GAAKMT2ACTSS | |
| SCHEMBL5558068 | 0.87 | TDP1 (0.62) | TDP1MEN1GAAKMT2ACTSS | |
| SCHEMBL31236472 | 0.87 | MAOA (0.54) | TDP1MEN1GAAKMT2ACTSS | |
| SCHEMBL15255730 | 0.87 | MAOA (0.57) | TDP1MEN1GAAKMT2ACTSS | |
| SCHEMBL21233506 | 0.86 | TDP1 (0.65) | TDP1MEN1GAAKMT2ACTSS | |
| SCHEMBL25353938 | 0.85 | MAOA (0.60) | TDP1MEN1GAAKMT2ACTSS | |
| SCHEMBL25353161 | 0.85 | MAOA (0.60) | TDP1MEN1GAAKMT2ACTSS | |
| SCHEMBL2247638 | 0.84 | TDP1 (0.46) | TDP1MEN1GAAKMT2ACTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704904-A1 | TETRAZINE-BASED TARGETING AGENTS FOR IN VIVO DELIVERY OF A PAYLOAD | Tambo, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-3474901-B1 | CLEAVABLE TETRAZINE USED IN BIO-ORTHOGONAL DRUG ACTIVATION | TAGWORKS PHARMACEUTICALS B V (NL) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025059685-A1 | METHODS FOR IN VIVO TARGETED DELIVERY OF A PAYLOAD | TAMBO, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| WO-2025043219-A1 | METHODS FOR UNCAGING TETRAZINES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-02-27 | — | — | WO | disclosed |
| US-12186405-B2 | Cleavable tetrazine used in bio-orthogonal drug activation | TAGWORKS PHARMACEUTICALS B.V. (NL) | 2025-01-07 | — | — | US | disclosed |
| WO-2024229427-A1 | TETRAZINE-BASED TARGETING AGENTS FOR IN VIVO DELIVERY OF A PAYLOAD | TAMBO, INC. (US) | 2024-11-07 | — | — | WO | disclosed |
| EP-4422696-A1 | TETRAZINE CONJUGATES FOR IN VIVO TARGETED DELIVERY OF A PAYLOAD | Tambo, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20240208992-A1 | MACROCYCLES AS CFTR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-06-27 | — | — | US | disclosed |
| WO-2024137426-A1 | PROCESS TO MAKE GLP1 RA AND INTERMEDIATES THEREFOR | ELI LILLY AND COMPANY (US) | 2024-06-27 | — | — | WO | disclosed |
| EP-4382167-A2 | COMPOUNDS COMPRISING A LINKER FOR INCREASING TRANSCYCLOOCTENE STABILITY | Tagworks Pharmaceuticals B.V. (NL) | 2024-06-12 | — | — | EP | disclosed |
| CN-101146811-A | HIV integrase inhibitors | ISTITUTO DE RICERCHE DI BIOLOG (IT) | 2008-03-19 | — | — | CN | disclosed |
| WO-2007072153-A2 | CARBONYLAMINO PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2007-06-28 | — | — | WO | disclosed |
| US-5414013-A | Enzyme inhibitors | E. R. SQUIBB & SONS, INC. (US) | 1995-05-09 | — | — | US | disclosed |
| US-5414017-A | Cardiovascular agents | E. R. SQUIBB & SONS, INC. (US) | 1995-05-09 | — | — | US | disclosed |
| US-5378706-A | Memory disorders, senile dememtia | SANOFI (FR) | 1995-01-03 | — | — | US | disclosed |
| EP-0449523-B1 | Mercapto- or acylthio-trifluoromethyl amide derivatives and their use | SQUIBB & SONS INC (US) | 1994-08-17 | — | — | EP | disclosed |
| WO-1993023402-A1 | 3-AZETIDINYLTHIO-CARBAPENEME DERIVATIVES, THEIR PREPARATION AND USE AS ANTIMICROBIAL AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-11-25 | — | — | WO | disclosed |
| US-5232921-A | Thiazole derivatives active on the cholinergic system, process for obtention and pharmaceutical compositions | SANOFI (FR) | 1993-08-03 | — | — | US | disclosed |
| US-5223516-A | Endopeptidase inhibitors | E. R. SQUIBB & SONS, INC. (US) | 1993-06-29 | — | — | US | disclosed |
| EP-0449523-A1 | Mercapto- or acylthio-trifluoromethyl amide derivatives and their use | E.R. SQUIBB & SONS, INC. (US) | 1991-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208992-A1 | MACROCYCLES AS CFTR MODULATORS | CFTR, PKD1, ARRB1 | TDP1 4270/4885MEN1 1575/4885GAA 2994/4885 |
| US-12186405-B2 | Cleavable tetrazine used in bio-orthogonal drug activation | KIT, TPSB2, BTD | TDP1 1334/4885MEN1 1811/4885GAA 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.